We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: RIPK1 inhibitor
MedXY News
EnglishTag

RIPK1 inhibitor

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseaseepidemiologybreast cancer

Latest news

Tag

Evaluating SAR443820, a RIPK1 Inhibitor, in Amyotrophic Lateral Sclerosis: Insights from the Phase 2 HIMALAYA Trial
NeurologyALSFRS-RAmyotrophic Lateral Sclerosis

Evaluating SAR443820, a RIPK1 Inhibitor, in Amyotrophic Lateral Sclerosis: Insights from the Phase 2 HIMALAYA Trial

By MedXY|Oct 5, 2026

This phase 2 trial assessed SAR443820, a RIPK1 inhibitor, in ALS patients; it showed no clinical efficacy and increased hepatic side effects, indicating limited therapeutic potential in ALS.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models